Loss of Nmp4 enhances bone gain from sclerostin antibody administration.
Bone anabolism
Osteoanabolics
Osteoporosis
Romosozumab-aqqg
Journal
Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
05
07
2023
revised:
22
08
2023
accepted:
30
08
2023
pmc-release:
01
12
2024
pubmed:
4
9
2023
medline:
4
9
2023
entrez:
3
9
2023
Statut:
ppublish
Résumé
Severe osteoporosis is often treated with one of three Food and Drug Administration (FDA)-approved osteoanabolics. These drugs act by (1) parathyroid hormone (PTH) receptor stimulation using analogues to PTH (teriparatide) or PTH-related peptide (abaloparatide) or by (2) monoclonal antibody neutralization of sclerostin, an innate Wnt inhibitor (Scl-mAb, romosozumab-aqqg). The efficacies of both strategies wane over time. The transcription factor Nmp4 (Nuclear Matrix Protein 4) is expressed in all tissues yet mice lacking this gene are healthy and exhibit enhanced PTH-induced bone formation. Conditional deletion of Nmp4 in mesenchymal stem progenitor cells (MSPCs) phenocopies the elevated response to PTH in global Nmp4
Identifiants
pubmed: 37660938
pii: S8756-3282(23)00224-7
doi: 10.1016/j.bone.2023.116891
pmc: PMC10591883
mid: NIHMS1933451
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116891Subventions
Organisme : NIA NIH HHS
ID : R21 AG078861
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073739
Pays : United States
Organisme : BLRD VA
ID : I01 BX005861
Pays : United States
Organisme : BLRD VA
ID : IK6 BX003783
Pays : United States
Organisme : BLRD VA
ID : I01 BX005154
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR053237
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR065971
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Calcif Tissue Int. 2023 Jul;113(1):110-125
pubmed: 37147466
J Bone Miner Res. 2012 Feb;27(2):374-89
pubmed: 22028311
Nat Rev Rheumatol. 2019 Feb;15(2):67-68
pubmed: 30610218
Genesis. 2002 Jun;33(2):77-80
pubmed: 12112875
Sci Rep. 2018 Sep 25;8(1):14338
pubmed: 30254311
Mol Endocrinol. 2015 Sep;29(9):1269-85
pubmed: 26244796
Endocrinology. 2011 Aug;152(8):2963-75
pubmed: 21652726
J Clin Pharmacol. 2014 Feb;54(2):168-78
pubmed: 24272917
Endocr Rev. 2021 Jul 16;42(4):383-406
pubmed: 33564837
J Biol Chem. 2016 Jun 24;291(26):13780-8
pubmed: 27129771
Stem Cells Dev. 2013 Feb 1;22(3):492-500
pubmed: 22873745
Nat Immunol. 2003 Apr;4(4):321-9
pubmed: 12612580
J Clin Invest. 2005 Sep;115(9):2402-11
pubmed: 16138191
J Cell Physiol. 2009 Jun;219(3):734-43
pubmed: 19189321
Bone Rep. 2022 Jan 04;16:101164
pubmed: 35028339
J Bone Miner Res. 2012 Oct;27(10):2075-84
pubmed: 22623172
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2732-6
pubmed: 1313566
J Biol Chem. 2005 Jul 22;280(29):26770-5
pubmed: 15908424
Nat Rev Mol Cell Biol. 2009 Jul;10(7):468-77
pubmed: 19536106
Calcif Tissue Int. 2011 Jul;89(1):74-89
pubmed: 21607813
Science. 1991 Nov 15;254(5034):1024-6
pubmed: 1658941
Bone. 2020 Jan;130:115121
pubmed: 31678488
Nat Med. 2011 Jun;17(6):684-91
pubmed: 21602802
Bone. 2015 Dec;81:380-391
pubmed: 26261096
J Biol Chem. 2005 May 20;280(20):19883-7
pubmed: 15778503
Mol Cell Biol. 2016 Nov 14;36(23):2945-2955
pubmed: 27644326
J Bone Miner Res. 2023 Jan;38(1):70-85
pubmed: 36321253
Mol Cell Biol. 2016 Nov 14;36(23):2931-2944
pubmed: 27644325
Bone. 2007 Jun;40(6):1453-61
pubmed: 17376756
Mucosal Immunol. 2021 Jan;14(1):209-218
pubmed: 32152414
Bone. 2007 Apr;40(4):852-60
pubmed: 17301008
J Bone Miner Res. 2001 Jan;16(1):10-23
pubmed: 11149472
J Biol Chem. 2002 Dec 13;277(50):49047-54
pubmed: 12374812
Biochemistry (Mosc). 2022 Sep;87(9):916-931
pubmed: 36180988
Endocrinology. 2008 Apr;149(4):1960-8
pubmed: 18187540
Bone. 2007 Apr;40(4):1135-43
pubmed: 17275432
Br J Clin Pharmacol. 2019 Jun;85(6):1084-1094
pubmed: 30218587
Cold Spring Harb Perspect Med. 2018 Aug 1;8(8):
pubmed: 29358318
J Bone Miner Res. 2013 May;28(5):1160-9
pubmed: 23188722
Cell Mol Gastroenterol Hepatol. 2019;8(4):549-560
pubmed: 31330316
Dev Cell. 2005 May;8(5):751-64
pubmed: 15866165
J Bone Miner Res. 2014 Jun;29(6):1424-30
pubmed: 24967455
PLoS One. 2011;6(10):e25900
pubmed: 21991382
Handb Exp Pharmacol. 2020;262:423-450
pubmed: 32232792
Endocrinology. 2017 Sep 1;158(9):2722-2740
pubmed: 28637206
J Bone Miner Res. 2017 Sep;32(9):1956-1962
pubmed: 28543940
J Clin Invest. 1999 Aug;104(4):439-46
pubmed: 10449436
Cell Metab. 2017 Mar 7;25(3):661-672
pubmed: 28162969
Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E749-E772
pubmed: 30645175
Nat Commun. 2019 Sep 3;10(1):3960
pubmed: 31481663
J Bone Miner Res. 2011 Jan;26(1):19-26
pubmed: 20593411
J Cell Biochem. 2016 Apr;117(4):970-7
pubmed: 26378628
Bioessays. 2012 Jan;34(1):10-6
pubmed: 22028036
PLoS One. 2011;6(6):e20780
pubmed: 21695256
Arch Osteoporos. 2011;6:59-155
pubmed: 22886101
J Bone Miner Metab. 2021 Jul;39(4):558-571
pubmed: 33721112
Genes Dev. 2017 Jan 15;31(2):154-171
pubmed: 28174210
Immunity. 2003 Feb;18(2):243-53
pubmed: 12594951
Front Biol (Beijing). 2015 Feb 1;10(1):28-51
pubmed: 25821458
Pharmacoepidemiol Drug Saf. 2023 Jun;32(6):671-684
pubmed: 36703260
J Bone Miner Res. 2020 Jan;35(1):36-52
pubmed: 31538675
J Bone Miner Res. 2021 Apr;36(4):757-767
pubmed: 33400836
Br J Clin Pharmacol. 2018 Feb;84(2):252-267
pubmed: 29049872
J Bone Miner Res. 2022 Feb;37(2):256-264
pubmed: 34738660
Bone. 2021 Feb;143:115708
pubmed: 33164872
Calcif Tissue Int. 2022 Feb;110(2):244-259
pubmed: 34417862
Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):
pubmed: 23209147
N Engl J Med. 2017 Oct 12;377(15):1417-1427
pubmed: 28892457